Clinical Trial Update: Phase 1, QT/QTC Interval Study in Healthy Subjects [Phase 1]

View source ↗

Summary

Vertex completed a Phase 1 QT/QTc interval safety study in healthy volunteers for a cystic fibrosis drug candidate (Lumacaftor, VX-809).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Lumacaftor (VX-809) (lumacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED